Anatara Lifesciences Limited Stock Market Press Releases and Company Profile
Anatara Expands Executive Team
Anatara Expands Executive Team

Brisbane, June 27, 2016 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.

Key points:

- CEO, Dr Paul Schober to retire and Chairman, Dr Mel Bridges to transition to Chairman & CEO role

- Dr Michael West appointed Chief Operating Officer (COO)

- Ms Kylie Davis appointed Clinical Trials Manager

The Company has accepted CEO, Dr Paul Schober's plans to move to retirement over the next three months as part of a closely managed transition plan, commencing Monday 27th June 2016.

Dr Bridges said, "We have a very close relationship with Paul, and expect this to be a smooth transition, aided strategically by a number of new appointments and a generous notice period. Paul has been critical to Anatara's early growth plans, following our 2014 ASX listing and played a key role in deploying the early strategic plan that has led the Company to the strong position that it's in today."

Anatara is also pleased to announce the appointment of Dr Michael West as Chief Operating Officer (COO), effective Friday 1st July 2016.

Dr West has extensive global GMP manufacturing, regulatory and drug launch scale-up expertise, including experience with global drug company SmithKline Beecham (now GSK) in the USA, Alchemia Limited and the Centre for Drug Design & Development at the University of Queensland. Dr West has served on the Pharmaceutical subcommittee to the Australian Drug Evaluation Committee at the Therapeutic Goods Administration (TGA).

Dr West will report directly to Dr Bridges and form part of the senior leadership team - also reporting to the board. Dr West will assume ownership for key areas of responsibility that have been managed to date by Dr Schober.

Dr Schober said, "I am very confident that Dr West will assume strategic management of my key responsibilities, and I will work closely with Michael over the next three months to ensure a seamless transition. I remain a founding shareholder of Anatara and am absolutely committed to making myself available to assist the team with executing the Company's strategic plans."

In a move to further strengthen its clinical trial capability, Anatara is pleased to announce the appointment of Ms Kylie Davis as its Clinical Trials Manager reporting to Co-Founder and CSO, Dr Tracey Mynott. Kylie was formerly a senior veterinary clinical research associate with leading global animal health company, Zoetis. She has over 9 years' experience coordinating and monitoring all aspects of veterinary clinical studies, both in Australia and internationally, including trials in pigs, cattle, poultry and in companion animals. She comes with experience in requirements for registration of veterinary products internationally.

Dr Bridges said, "The new executive team appointments will provide Dr Mynott more time to focus on moving the animal health initiatives to completion, as the Company increases its over-the-counter (OTC) opportunities in the human area."

"I am looking forward to re-assuming a leadership role in corporate communications and investor relations. I have purposefully scaled back my corporate commitments over the course of this year to give me the time to provide focussed commitment to Anatara. As the Company's largest shareholder I have a strong vested interest in ensuring we execute on our strategic goals," Dr Bridges added.

The Anatara team plans a further market update and investor roadshow in July.

About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit



Investor and Media inquiries:
Dr Mel Bridges
Chairman, Anatara Lifesciences
Phone: +61-413-051-600

Dr Tracey Mynott
CSO, Anatara Lifesciences
Phone: +61-405-050-113

Jane Lowe
IR department
Phone: +61-411-117-774

Related Companies

IR Department
Anatara Lifesciences Limited

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 5) (Last 30 Days: 15) (Since Published: 5231)